[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "summary": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=41b0789517ad596d3a2ea56ad084e917bfd29d50cd5ce016662a3ed0fbea8576",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758904560,
      "headline": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "id": 136923873,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=41b0789517ad596d3a2ea56ad084e917bfd29d50cd5ce016662a3ed0fbea8576"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move […]",
    "url": "https://finnhub.io/api/news?id=453ccbec71ac02283b18402f3191b4daef8aeefb35ff39bbac95eba022dc6d5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758898129,
      "headline": "JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating",
      "id": 136892832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares. While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move […]",
      "url": "https://finnhub.io/api/news?id=453ccbec71ac02283b18402f3191b4daef8aeefb35ff39bbac95eba022dc6d5e"
    }
  },
  {
    "ts": null,
    "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
    "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
    "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885865,
      "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
      "id": 136892883,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645808639/image_1645808639.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
      "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741"
    }
  }
]